NCT07731139RecruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have Obesity
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO INVESTIGATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ASCENDING ORAL DOSES OF PF-08642534 IN ADULTS WITH OBESITY
Source: ClinicalTrials.gov · Last updated 23 Sept 2026
Brief summary (registry, in English)
This study will look at a study drug called PF-08642534 in people with obesity (have too much body weight) to see: if participants can take different amounts (doses) of the study drug in a safe way and how adults with obesity tolerate it, and how the body handles the study drug (for example, how the study drug is absorbed and removed from the body). People who want to join the study will first go through a screening period of up to 4 weeks. Doctors will check if each person meets the study conditions, including age, body weight, and general health. People with certain medical conditions will not be able to take part in the study.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 24 Jul 2026
- Start date
- 28 Jul 2026
- Primary completion date
- 21 Apr 2027
- Lead sponsor
- Pfizer
- Diseases
- Obesity
- NCT number
- NCT07731139
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 120
- From 28 Jul 2026 to the primary completion date, 21 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Inclusion:
- Body mass index (BMI) ≥30.0 and ≤40.0 kg/m², and with stable body weight prior to screening.
- Participants are generally otherwise healthy but may have mild chronic conditions (eg, dyslipidemia or hypertension)
- Exclusion:
- \- Individuals with diabetes, significant cardiovascular, hepatic, renal, gastrointestinal, or psychiatric disorders, or conditions that may affect drug absorption or metabolism, are not eligible to participate.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Orange County Research Center Coordinator of this site? Confirm its status | Lake Forest | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.